This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The increasing prevalence of these conditions is driving demand for innovative solutions and improved management strategies. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Subscribe Today! Subscribe Today!
Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. TVM also invests in differentiated commercial-stage medicaltechnologies and late clinical-stage therapeutics.
Dedicated Facilities: The new EIT Oxford campus includes over 30,000 square meters of research laboratory space, an oncology and wellness clinic, and facilities like AI GPU Supercluster Lab, Drug Design Lab, and Medical Device Lab, specifically dedicated to healthcare technology advancements. Visit www.nelsonadvisors.co.uk
We believe our pioneering technology will allow us to shatter the boundaries that exist in gene editing methods today,” said Anne-K. Both Wellington and Forbion are visionaries and highly experienced biotech investors, and we look forward to working closely with them in our efforts to transform the gene editing landscape.” “Our
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content